By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aileron Therapeutics 

281 Albany Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-995-0900 Fax: 617-995-2410



Company News
Aileron Therapeutics Added To The Russell 2000, Russell 3000 And Russell Microcap Indexes 9/19/2017 10:15:54 AM
Aileron Therapeutics Announces Presentation Of Preclinical Data With ALRN-6924 At The International Society Of Experimental Hematology Annual Scientific Meeting 8/24/2017 8:21:17 AM
Aileron Therapeutics Reports Second Quarter 2017 Financial Results 8/11/2017 11:02:12 AM
Aileron Therapeutics Announces Pricing Of Initial Public Offering 6/29/2017 9:38:12 AM
Aileron Therapeutics Appoints Donald Dougherty As Senior Vice President And Chief Financial Officer 6/15/2017 6:33:03 AM
Aileron Therapeutics Files For $69 Million IPO As New Offerings Heat Up 6/6/2017 6:50:55 AM
Aileron Therapeutics Release: Anti-Tumor Activity Observed In Phase I Trial Of Novel P53-Targeting Drug ALRN-6924 6/5/2017 10:42:02 AM
Aileron Therapeutics Announces Oral Presentation At ASCO On ALRN-6924 Targeting p53 5/18/2017 7:10:07 AM
Aileron Therapeutics Initiates Phase 1 Cancer Study Of ALRN-6924 In Advanced Hematologic And Solid Malignancies With Wild Type P53 2/12/2015 10:04:13 AM
Aileron Therapeutics Appoints Evan Lippman As Chief Financial And Business Officer 1/8/2015 10:52:30 AM